D.E. Shaw & Co
KALV

D.E. Shaw & Co’s KalVista Pharmaceuticals KALV Stock Holding History

D.E. Shaw & Co’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-21,100
Closed -$257K – 4811
2025
Q3 		$257K Sell
21,100
-4,620
-18% -$63.8K ﹤0.01% 4187
2025
Q2 		$291K Hold
25,720
– – ﹤0.01% 3892
2025
Q1 		$297K Sell
25,720
-47,566
-65% -$485K ﹤0.01% 3763
2024
Q4 		$621K Sell
73,286
-16,643
-19% -$172K ﹤0.01% 3484
2024
Q3 		$1.04M Sell
89,929
-10,132
-10% -$127K ﹤0.01% 3246
2024
Q2 		$1.18M Buy
100,061
+12,968
+15% +$151K ﹤0.01% 3077
2024
Q1 		$1.03M Sell
87,093
-1,670
-2% -$22.3K ﹤0.01% 3072
2023
Q4 		$1.09M Sell
88,763
-26,519
-23% -$241K ﹤0.01% 3084
2023
Q3 		$1.11M Sell
115,282
-1,580
-1% -$16.1K ﹤0.01% 3000
2023
Q2 		$1.05M Buy
116,862
+71,198
+156% +$656K ﹤0.01% 3055
2023
Q1 		$359K Buy
45,664
+1,851
+4% +$13.8K ﹤0.01% 3686
2022
Q4 		$296K Sell
43,813
-456
-1% -$2.44K ﹤0.01% 4092
2022
Q3 		$642K Sell
44,269
-10,707
-19% -$150K ﹤0.01% 3885
2022
Q2 		$541K Buy
+54,976
New +$606K ﹤0.01% 4047
2020
Q3 		– Sell
-14,705
Closed -$178K – 3987
2020
Q2 		$178K Buy
+14,705
New +$156K ﹤0.01% 3803

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

D.E. Shaw & Co's KALV Position: Q4 2025 in Review

D.E. Shaw & Co sold out of KalVista Pharmaceuticals (KALV) in Q4 2025, closing a stake of 21,100 shares — an estimated $257K sold.

D.E. Shaw & Co first reported a position in KALV in Q2 2020 and held it in 15 quarters. The position peaked at $1.18M in Q2 2024. 161 funds tracked by Wall St. Rank hold KALV as of Q4 2025.

  • D.E. Shaw & Co reported no remaining KalVista Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 21,100 KalVista Pharmaceuticals shares in Q4 2025, an estimated $257K.
  • D.E. Shaw & Co first reported a position in KalVista Pharmaceuticals in Q2 2020 and held it in 15 quarters.
  • D.E. Shaw & Co's KalVista Pharmaceuticals position peaked at $1.18M in Q2 2024.
  • 161 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2025.

Based on D.E. Shaw & Co's 13F filing for Q4 2025, filed 17 Feb 2026.